Bioventix PLC
BVXP.L
Get informed when a big investor buys or sells
+ FollowMarket Cap$8.75B
Close$
$2750.78
64.2% upside
Current Fair Value
64.2% upsideUndervalued by 64.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $8.75 Billion |
|---|---|
| Enterprise Value | $8.75 Billion |
| Dividend Yield | $150.00 (8.22%) |
| Earnings per Share | $1.45 |
| Beta | 0.54 |
| Outstanding Shares | 5,224,974 |
Return
| Return on Equity | 138.41% |
|---|---|
| Return on Assets | 117.25% |
| Return on Invested Capital | 178.51% |
Valuation & Multiples
| P/E Ratio | 12.85 |
|---|---|
| PEG | -329.11 |
| Price to Sales | 335.0 |
| Price to Book Ratio | 837.5 |
| Enterprise Value to Revenue | 333.76 |
| Enterprise Value to EBIT | 443.74 |
| Enterprise Value to Net Income | 572 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Next Earnings Call
Expected Date
October 26, 2026
EPS Estimate
$0.66
Average shareholder expectationRevenue Estimate
$6.34 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Bioventix PLC
12 employees
CEO: Peter John Harrison Bioventix PLC focuses on the development, manufacturing, and global provision of sheep monoclonal antibodies (SMAs) for various diagnostic purposes. The company's extensive product line features purified SMAs that facilitate testing for ...